Native Mass Spectrometry in Fragment-Based Drug Discovery
AbstractThe advent of native mass spectrometry (MS) in 1990 led to the development of new mass spectrometry instrumentation and methodologies for the analysis of noncovalent protein–ligand complexes. Native MS has matured to become a fast, simple, highly sensitive and automatable technique with well-established utility for fragment-based drug discovery (FBDD). Native MS has the capability to directly detect weak ligand binding to proteins, to determine stoichiometry, relative or absolute binding affinities and specificities. Native MS can be used to delineate ligand-binding sites, to elucidate mechanisms of cooperativity and to study the thermodynamics of binding. This review highlights key attributes of native MS for FBDD campaigns. View Full-Text
Share & Cite This Article
Pedro, L.; Quinn, R.J. Native Mass Spectrometry in Fragment-Based Drug Discovery. Molecules 2016, 21, 984.
Pedro L, Quinn RJ. Native Mass Spectrometry in Fragment-Based Drug Discovery. Molecules. 2016; 21(8):984.Chicago/Turabian Style
Pedro, Liliana; Quinn, Ronald J. 2016. "Native Mass Spectrometry in Fragment-Based Drug Discovery." Molecules 21, no. 8: 984.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.